Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Acetylcysteine
/ therapeutic use
Adolescent
Amifostine
/ therapeutic use
Anti-Inflammatory Agents
/ therapeutic use
Antineoplastic Agents
/ adverse effects
Chelating Agents
/ therapeutic use
Child
Cisplatin
/ adverse effects
Cytoprotection
Dexamethasone
/ therapeutic use
Disulfiram
/ therapeutic use
Ditiocarb
/ therapeutic use
Humans
Neoplasms
/ drug therapy
Ototoxicity
/ etiology
Thiosulfates
/ therapeutic use
Journal
The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
08
02
2019
revised:
11
03
2019
accepted:
13
03
2019
pubmed:
5
6
2019
medline:
26
5
2020
entrez:
5
6
2019
Statut:
ppublish
Résumé
The identification of preventive interventions that are safe and effective for cisplatin-induced ototoxicity is important, especially in children because hearing loss can impair speech-language acquisition development. Previous randomised trials assessed systemic drugs such as amifostine, sodium diethyldithiocarbamate or disulfiram, and sodium thiosulfate. Amifostine, sodium diethyldithiocarbamate, and disulfiram did not show hearing preservation. Paediatric trials assessing sodium thiosulfate showed efficacy in terms of hearing protection. The SIOPEL 6 trial consisted solely of patients with localised hepatoblastoma and no effects on survival were shown. In the ACCL0431 trial, which included heterogeneous patients, a post-hoc analysis showed significantly worse overall survival among patients who had disseminated disease receiving sodium thiosulfate than among controls, but not among those with localised disease. Intratympanically administered drugs have mainly been assessed in adults and include N-acetylcysteine and dexamethasone. Inconsistent effects of these drugs were identified but these studies were limited by design, small sample size, and statistical approach. Future studies of systemic drugs will need to consider the measurement of disease outcomes through study design and sample size, and ototoxicity endpoints should be harmonised to enhance comparability between trials.
Identifiants
pubmed: 31160205
pii: S2352-4642(19)30115-4
doi: 10.1016/S2352-4642(19)30115-4
pmc: PMC7521148
mid: NIHMS1627109
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antineoplastic Agents
0
Chelating Agents
0
Thiosulfates
0
Dexamethasone
7S5I7G3JQL
Ditiocarb
99Z2744345
sodium thiosulfate
HX1032V43M
Amifostine
M487QF2F4V
Cisplatin
Q20Q21Q62J
Disulfiram
TR3MLJ1UAI
Acetylcysteine
WYQ7N0BPYC
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-584Subventions
Organisme : Cancer Research UK
ID : 8156
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA137488
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA168526
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189955
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
J Clin Oncol. 1988 Jun;6(6):955-62
pubmed: 2836565
Pediatr Hematol Oncol. 2007 Sep;24(6):403-8
pubmed: 17710657
Clin Cancer Res. 2008 Jan 15;14(2):533-40
pubmed: 18223229
J Clin Oncol. 1995 May;13(5):1231-7
pubmed: 7738626
Int J Pediatr Otorhinolaryngol. 2018 Apr;107:75-79
pubmed: 29501316
Br J Clin Pharmacol. 1996 Aug;42(2):233-5
pubmed: 8864323
Neuro Oncol. 2014 Aug;16(8):1129-36
pubmed: 24497405
J Clin Oncol. 2003 May 15;21(10):2011-8
pubmed: 12743156
Eur J Cancer. 2017 Dec;87:75-83
pubmed: 29128692
Hear Res. 2004 Jul;193(1-2):25-30
pubmed: 15219317
Otolaryngol Head Neck Surg. 2014 Jun;150(6):983-90
pubmed: 24618499
J Otolaryngol. 1991 Jun;20(3):158-67
pubmed: 1870163
N Engl J Med. 2018 Jun 21;378(25):2376-2385
pubmed: 29924955
Eur J Pharmacol. 1999 Jan 29;366(1):47-53
pubmed: 10064151
Int Tinnitus J. 2018 Jun 01;22(1):40-45
pubmed: 29993216
J Clin Oncol. 2016 Dec;34(34):4151-4160
pubmed: 27863192
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Oncologist. 2018 Jul;23(7):762-e79
pubmed: 29445029
Lancet. 2002 Jan 19;359(9302):248-52
pubmed: 11812579
J Clin Oncol. 1995 Feb;13(2):490-6
pubmed: 7844610
Head Neck. 2016 Apr;38 Suppl 1:E2118-21
pubmed: 26849799
Am J Clin Oncol. 2013 Feb;36(1):1-6
pubmed: 22134515
Ann Oncol. 1999 Jun;10(6):693-700
pubmed: 10442192
Wien Klin Wochenschr. 2000 Jul 28;112(14):617-23
pubmed: 11008323
J Clin Oncol. 1996 Jul;14(7):2101-12
pubmed: 8683243
Int Tinnitus J. 2015;19(2):12-9
pubmed: 27186927
Kulak Burun Bogaz Ihtis Derg. 2010 Jul-Aug;20(4):173-83
pubmed: 20626325
Pediatr Blood Cancer. 2014 May;61(5):840-5
pubmed: 24254749
Front Cell Neurosci. 2017 Sep 13;11:268
pubmed: 28955202
Eur J Cancer. 2004 Jul;40(11):1713-23
pubmed: 15251161
J Clin Oncol. 2017 Feb;35(4):440-445
pubmed: 27937095
Am J Clin Oncol. 1990 Apr;13(2):119-24
pubmed: 2180271
Cancer. 2009 Dec 15;115(24):5828-35
pubmed: 19813275
Lancet Oncol. 2017 Jan;18(1):63-74
pubmed: 27914822
J Clin Oncol. 2012 Jul 1;30(19):2408-17
pubmed: 22547603
J Clin Oncol. 2015 Jan 10;33(2):195-201
pubmed: 25452439
Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1521-34
pubmed: 21999330
Biomed Microdevices. 2018 Jun 8;20(2):47
pubmed: 29884927
Laryngoscope. 2014 Mar;124(3):E87-94
pubmed: 23946126
Pediatr Hematol Oncol. 2017 Mar;34(2):120-129
pubmed: 28590156
Pediatrics. 2007 Nov;120(5):e1229-36
pubmed: 17974716
Health Promot Chronic Dis Prev Can. 2017 Nov;37(11):393
pubmed: 29119777
Ann Oncol. 2001 Aug;12(8):1151-5
pubmed: 11583199